Diagnostic accuracy of salivary biomarkers of bone turnover in identifying patients with periodontitis in a Saudi Arabian population

Joseph Betsy a*, Javali Mukhatar Ahmed a, Abdul Khader Mohasin a, Amanullah Mohammed b, AlQahtani Nabeeh A. a

a Department of Periodontics and Community Dental Sciences, Division of Periodontics, College of Dentistry, King Khalid University, Abha, Saudi Arabia
b Department of Clinical Biochemistry, College of Medicine, King Khalid University, Gureiger, Abha, Saudi Arabia

Received 29 November 2018; Final revision received 6 March 2019
Available online 29 March 2019

KEYWORDS
Salivary; C-terminal telopeptide region of type I collagen (CTX); Osteocalcin (OC); Osteonectin (ON); Alveolar bone loss (BL); Probing pocket depth (PPD)

Abstract  Background/purpose: Salivary markers of bone turnover are useful biomarkers for screening patients advanced periodontal diseases with alveolar bone loss. Hence, the purpose of this study was to determine the diagnostic accuracy of deoxypyridinoline-containing degradation fragment of the C-terminal telopeptide region of type I collagen (CTX), Osteocalcin (OC) and Osteonectin (ON) in identifying patients with alveolar bone loss (BL) due to periodontitis. Materials and method: Salivary levels of CTX, OC and ON were evaluated in ninety patients (group I, II and III with healthy, periodontitis without Type2 diabetes mellitus-T2DM and periodontitis with T2DM respectively). Group III was included since T2DM is very common among patients attending our clinics. Bleeding on probing (BOP), probing pocket depth (PPD) and BL were recorded for these patients. Results: The concentrations of salivary CTX, OC, and ON were higher in subjects with periodontitis than in controls. Significant correlations were found between these biomarkers and periodontal parameters. CTX, OC, and ON could discriminate between healthy (group I) and diseased (group II & III) regarding BL with excellent sensitivity (90.2–100%) and good specificity (62.1–96.6%). ROC curve gave excellent discrimination regarding BL (AUC: 0.926–0.958) and PPD (AUC: 0.904–0.915). However, none of the cut-off values gave good discrimination regarding BOP.

* Corresponding author. Division of Periodontics, College of Dentistry, King Khalid University, PO Box No 3263, Abha, Saudi Arabia. E-mail address: bjoseph@kku.edu.sa (J. Betsy).

https://doi.org/10.1016/j.jds.2019.03.002
1991-7902/© 2019 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Conclusion: It can be concluded that CTX, OC, and ON correlated well with BL and PPD. Among the three biomarkers, ON at 81.80 ng/ml gave the best discrimination for presence or absence of bone loss.

Materials and methods

Subjects

In this cross-sectional study, one hundred eighty-seven consecutive patients who attended clinics of Department of Periodontics at College of Dentistry of King Khalid University (May to December 2018) were evaluated for eligibility for participation. Patients between the age group of 25–75 years were examined for eligibility. Those who agreed to the protocol signed informed consent and were included in the study as shown in Fig. 1. The study protocol was approved by Institutional review board and ethical approval was sought from the Scientific research committee, College of Dentistry of King Khalid University, Abha, Saudi Arabia (Approval no. SRC/ETH/2017-18/061). The
study was conducted in full accordance with ethical principles, including the World Medical Association Declaration of Helsinki (version 2008). In accordance with the classification by American Academy of Periodontology (2018), patients were grouped as healthy (n = 30 in Group I) and periodontally diseased (n = 30 in Group II and III each). Periodontitis without Type2 Diabetes mellitus (T2DM) was included in Group II while periodontitis with T2DM was in Group III. Following the American Diabetes Association (ADA) criteria, group III patients had T2DM with (glycated hemoglobin) Hb A1c level ≥7% and were on oral anti-hyperglycemic drugs. Patients with any other systemic diseases, any medication other than oral anti-hyperglycemic drugs, the habit of smoking, artificial joints, periodontal therapy within three months or systemic antibiotics within last three months, current use of corticosteroids or non-steroidal anti-inflammatory drugs and lactating or pregnant ladies were excluded from the study. Patients needing complex rehabilitation (stage 4) according to the new classification of periodontitis and less than 20 remaining teeth were also not included due to the vast extent of periodontal destruction.

**Clinical examination**

The primary outcome was the radiographic assessment of alveolar bone loss (BL). The amount of bone loss in the worst affect tooth in each patient was measured from cementoenamel junction to crest of alveolar bone and expressed as a proportion of its root length. The procedure was standardized by parallel technique (Kodak Ultra speed Dental Film, Eastman Kodak, Rochester, NY, USA) with a Siemens Heliodent MD model X1744 (Sirona Dental Systems, GmbH D-64625, Bensheim, Germany) and the X-ray machine was used at 70 kV and 7 mA.

BOP was measured according to gingival bleeding index. PPD was measured using a periodontal probe (University of Michigan O probe with William’s markings) by a double pass method by a single trained examiner for all patients. Absence or up to 15% of BL, BOP less than 10% and PPD less than 4.0 mm were considered as absence of periodontitis disease.

**Protocol for estimation of salivary bone biomarkers**

Unstimulated whole saliva was collected by a clinician from each patient in the morning (9–10 am) before periodontal probing to prevent mixing of blood or GCF with saliva. Saliva was collected into a sterile 5 ml vial after they rinsed the mouth thoroughly with for 30 s and expectorated. The vials with salivary samples were sealed, labeled for identification and placed in a Styrofoam box containing ice after which it was sent to the Clinical Biochemistry laboratory at the College of Medicine, King Khalid University, for storage (at −80°C) till further analysis by an experienced senior member in Clinical Biochemistry. Antibody sandwich Enzyme-Linked Immunosorbent Assay (ELISA) was performed for the estimation of the biochemical constituents in the collected salivary samples. Commercially available ELISA kits for Human ICTP (Cross Linked C-telopeptide of Type I Collagen) (Catalog No: E-EL-H0835), Human OC/BGP (Osteocalcin) ELISA Kit (Catalog No: E-EL-H1343) were procured from Elabscience Biotechnology Inc, Houston, TX, USA and Human SPARC (Osteonectin) ELISA Kit (Catalog No: AB220654) from Abcam, Cambridge, UK, were procured for the estimation. The levels of these constituents were estimated according to manufacturers’ instructions. The analytical performance of the assay(s) was validated to confirm the manufacturer’s analytical performance claims.

**Statistical analysis**

In descriptive statistics, all quantitative data were expressed as mean ± SD, whereas qualitative data in numbers and percentiles. Normality assumption was made. Inferential statistics includes analysis of all variables for the mean values, SD and p value. The statistical comparison of qualitative variables like oral hygiene practices and quantitative variables like periodontal and various salivary biomarkers between study groups was performed by chi-
square test and analysis of variance (ANOVA) along with Post Hoc (Bonferroni for multiple comparison) respectively at 95% Confidence interval (CI). Correlation analysis between various periodontal variables with salivary biomarkers was done using Pearson’s correlation analysis and the result was expressed with p-value and Pearson’s Coefficient. Receiver operator characteristics (ROC) curve was fitted into the data to determine the predictability of biomarkers based on binary assumption. Sensitivity (Se), Specificity (Sp), area under curve (AUC) and Youden’s index (YI) at 95% CI were calculated for BL, BOP, and PPD.

Results

Out of one hundred eighty-seven consecutive patients examined, hundred and six patients were considered eligible to participate in the study. Sixteen patients dropped out during the study as six of them (three males and three females) refused to give saliva for the study and ten out during the study as six of them (three males and three females) refused to give saliva for the study and ten (females) expressed inconvenience while taking radiographs after initially agreeing upon it. Hence, there were fifty-three males and twenty-seven females who completed the study. Descriptive statistics were done for the demographic data between study groups (Table 1).

Table 2 shows the comparison of variables related to oral hygiene practices and clinical variables while Table 3 shows that BOP, PDD, BL (p < 0.001) and salivary CTX, OC and ON (p < 0.001) demonstrated a statistically significant (p < 0.001) gradual increasing trend from group I to group III. Details of post hoc analysis for comparative analysis of different salivary biomarkers between different study groups are given in Table 4. Following this, correlation analysis was performed between periodontal variables with salivary biomarkers (CTX, OC, and ON) using Pearson Correlation (95% CI) as shown in Table 5. It showed positive correlation of CTX with PPD (r = 0.79) and BL (r = 0.82) (p < 0.001) and BOP (r = 0.28) (p < 0.01). OC and ON showed a similar positive correlation with BOP, PPD and BL.

It was found that CTX, OC and ON could discriminate between healthy and diseased regarding BL with excellent sensitivity (90.2–100%) and good specificity (62.1–96.6%) using the various cut off values obtained from coordinates of ROC. Similarly, regarding PPD, excellent sensitivity (94.4–100%) and fair to good specificity (63.9–83.3%), ROC curve gave excellent discrimination regarding BL (AUC: 0.926–0.958) and PPD (AUC: 0.904–0.915). Figs. 2–4 show the ROC curve for BL, PPD and BOP. Table 6 describes cut off values, sensitivity, specificity, area under curve of ROC. Similarly, regarding PPD, excellent sensitivity (94.4–100%) and fair to good specificity (63.9–83.3%), ROC curve gave excellent discrimination regarding BL (AUC: 0.926–0.958) and PPD (AUC: 0.904–0.915). Figs. 2–4 show the ROC curve for BL, PPD and BOP. Table 6 describes cut off values, sensitivity, specificity, area under curve of ROC and Youden index for CTX, OC and ON in discriminating healthy from periodontitis in terms of BOP, PPD, and BL. Among the three biomarkers, ON at 81.80 ng/ml gave the overall best discrimination which was for the presence or absence of BL (YI = 0.91). CTX discriminated best (YI = 0.88) at 29.86 ng/ml between presence or absence of BL. CTX and ON discriminated well between presence and absence of PPD too at 29.86 ng/ml and 72.85 ng/ml respectively (YI = 0.83). However, the none of the cut off values gave good discrimination regarding BOP.

Discussion

Our results confirm that there exists a correlation between CTX, OC and ON and alveolar bone loss. Our results also show that these biomarkers in the saliva can discriminate between presence and absence of BL and PDD but not for BOP. Similar correlation studies have been done by few other research groups to determine whether a relationship exists between clinical parameters of periodontal disease and salivary bone turnover biomarkers.4–6,22 PPD which is the most important clinical feature of periodontal disease also showed correlation with these biomarkers. Levels of salivary CTX and OC in healthy showed greater variation

| Demographic Variables - (Expressed as N (%) – Except Age) | Group I | Group II | Group III | Total |
|----------------------------------------------------------|---------|---------|-----------|-------|
| Gender                                                   |         |         |           |       |
| Male                                                     | 19 (63.3) | 14 (46.7) | 20 (66.7) | 53 (58.9) |
| Female                                                   | 11 (36.7) | 16 (53.3) | 10 (33.3) | 37 (41.1) |
| Age                                                      | 33.00 ± 9.70 | 41.30 ± 9.32 | 40.87 ± 10.88 | — |
| Occupation                                               |         |         |           |       |
| None                                                     | 0       | 5 (16.7) | 2 (6.7)  | 7 (7.8)  |
| Unskilled                                                | 6 (20.0) | 7 (23.3) | 8 (26.7) | 21 (23.3) |
| Semi-Skilled                                             | 19 (63.3) | 13 (43.3) | 15 (50.0) | 47 (52.2) |
| Professional                                             | 5 (16.7) | 5 (16.7) | 5 (16.7) | 15 (16.7) |
| Education                                                |         |         |           |       |
| Below 5th grade                                          | 0       | 3 (10)   | 0         | 3 (3.3)   |
| Primary School                                           | 3 (10.0) | 9 (30)   | 10 (33.3) | 22 (24.4) |
| High School                                              | 20 (66.7) | 11 (36.7) | 15 (50.0) | 46 (51.1) |
| Graduate/Post graduate                                   | 7 (23.3) | 7 (23.3) | 3 (20)    | 19 (21.1) |
| Income                                                   |         |         |           |       |
| Below 4 K Saudi riyals                                   | 0       | 0       | 0         | 0       |
| 4K-6 K Saudi riyals                                      | 2 (6.7) | 5 (16.7) | 0         | 7 (7.8)  |
| 6K-10 K Saudi riyals                                     | 13 (43.3) | 12 (40.0) | 14 (46.7) | 39 (43.3) |
| Above 10 K Saudi riyals                                  | 15 (50.0) | 13 (43.3) | 16 (53.3) | 44 (48.9) |
| Diabetes Status                                          |         |         |           |       |
| Absent (Hb A1c < 7%)                                      | 30 (100) | 30 (100) | 0        | 60      |
| Present (Hb A1c ≥ 7%)                                     | 0       | 0       | 30 (100)  | 30      |

Note: SD: Standard Deviation.
than ON. CTX had a statistically significant overall positive correlation with BL and PPD. The correlation with BL is similar to few previous studies.8,9 The good diagnostic accuracy of CTX levels in oral fluids has suggested it as a potential diagnostic marker of increased bone destruction.8,9 CTX has been suggested to correlate with clinical parameters of periodontal disease and to reduce following periodontal therapy, thus leading to an accurate assessment of tissue breakdown.23,24 In this study, the levels of ON correlated positively with alveolar bone loss and PPD. This is contrary to the negative correlation of SPARC/osteonectin in terms of bone loss in patients with periodontal disease.4,23 Increased levels of ON in the diseased groups could be due to the potential for SPARC/osteonectin to enhance healing of degraded alveolar bone with collagen deposition.12 It is found that lack of SPARC/osteonectin caused decreased total collagen and its production was decreased by periodontal disease. So, it appears that SPARC/osteonectin is a strong candidate for monitoring disease and improvement following treatment.

Table 2 Comparative analysis of variables related to oral hygiene practices and periodontal variables between study groups.

| Variable              | Group I (%) | Group II (%) | Group III (%) | Total | p-value |
|-----------------------|-------------|--------------|---------------|-------|---------|
| Oral Hygiene Tool     |             |              |               |       |         |
| Toothbrush            | 9 (30.0)    | 8 (26.7)     | 12 (40)       | 29 (32.2) | 0.91a   |
| Miswak                | 14 (46.7)   | 16 (53.3)    | 14 (46.7)     | 44 (48.9) |         |
| Other                 | 7 (23.3)    | 6 (20.0)     | 4 (13.3)      | 17 (18.9) |         |
| Frequency of Brushing |             |              |               |       |         |
| Once                  | 14 (46.7)   | 16 (53.3)    | 13 (43.3)     | 43 (47.8) | 0.82a   |
| Twice                 | 10 (33.3)   | 7 (23.3)     | 5 (16.7)      | 22 (24.4) |         |
| Other                 | 6 (20.0)    | 7 (23.3)     | 12 (40)       | 25 (27.8) |         |
| Time taken for brushing (In minutes) | Mean ± SD |               |               |       |         |
|                       | 1.67 ± 1.44 | 1.43 ± 1.04  | 1.33 ± 1.17   | —     | 0.72b   |
| BOP                   |             |              |               |       |         |
| <10%                  | 5 (16.7)    | 3 (10.0)     | 0             | 8 (8.9) | 0.000d  |
| ≥10%                  | 25 (83.3)   | 27 (90.0)    | 30 (100)      | 82 (91.1) |         |
| PPD                   |             |              |               |       |         |
| ≤4.0 mm               | 30 (100)    | 4 (13.3)     | 26 (86.7)     | 54 (60.0) |         |
| ≥4.0 mm               | 0           | 28 (93.3)    | 28 (93.3)     | 54 (60.0) |         |
| Bone Loss             |             |              |               |       |         |
| <15%                  | 30 (100.0)  | 2 (6.7)      | 0             | 32 (32.2) | 0.000d  |
| ≥15%                  | 0           | 28 (93.3)    | 30 (100)      | 58 (67.8) |         |

§ p value < 0.001; SD: Standard Deviation; PPD: Probing pocket depth.  
a Chi square test.  
b One Way ANOVA.

Table 3 Comparative analysis of periodontal variables and salivary biomarkers of bone turnover between study groups.

| Variable                  | Periodontal Variables (Mean ± SD) | p value |
|---------------------------|-----------------------------------|---------|
|                           | Group I                           | Group II | Group III |
| BOP                       | 9.4 ± 3.84                        | 37.36 ± 17.90 | 47.07 ± 18.17 | 0.000d |
| PPD (mm)                  | 2.56 ± 0.63                       | 5.13 ± 0.71  | 5.56 ± 0.79  | 0.000d |
| Bone Loss (mm)            | 9.50 ± 4.84                       | 22.75 ± 5.83 | 30.94 ± 6.10 | 0.000d |
| Salivary biomarkers of bone turnover (Mean ± SD) |          |          |           |
| CTX (ng/ml)               | 14.45 ± 3.63                      | 61.90 ± 11.57 | 70.63 ± 10.28 | 0.000d |
| Osteocalcin (ng/ml)       | 8.93 ± 5.80                       | 24.99 ± 8.97  | 34.40 ± 7.27  | 0.000d |
| Osteonectin (ng/ml)       | 52.61 ± 8.93                      | 109 ± 20.48   | 119.84 ± 16.01 | 0.000d |
| Percentage variation in salivary biomarkers of bone turnover with respect to healthy control |          |          |           |
| CTX (ng/ml)               | —                                 | 76.65%      | 79.54%     |
| Osteocalcin (ng/ml)       | —                                 | 76.27%      | 74.04%     |
| Osteonectin (ng/ml)       | —                                 | 51.73%      | 56.46%     |
| Percentage variation in salivary biomarkers of bone turnover with respect to adjacent group |          |          |           |
| CTX (ng/ml)               | —                                 | 76.65%      | 14.10%     |
| Osteocalcin (ng/ml)       | —                                 | 76.27%      | 27.35%     |
| Osteonectin (ng/ml)       | —                                 | 51.73%      | 9.04%      |

Note: ¶ p value < 0.001; PPD: Periodontal Pocket Depth; SD: Standard Deviation.
of OC with pocket depth, gingival index scores were observed. On the contrary, negligible or negative correlation between severity of periodontitis and OC also have been observed.\(^7,25,27\) Increased OC levels seen in diseased patients could be due to increased periodontal disease activity. This could be explained on the fact that OC is known to act as a chemoattractant for osteoclasts\(^28\) and essential for osteoclast differentiation. However, this is contrary to some studies that found biomineralization followed secretion of OC, which may reflect early osteoblastic differentiation. Moreover, it is suggested that OC might be an active regulator of insulin sensitivity by bone.\(^29\) ON has also been found to predispose the body to insulin resistance, thus represent a novel and important link between obesity and diabetes mellitus.\(^30\) This could be explained since in diabetes, periodontal membrane and the dilation of blood vessels, hemorrhage has also been a significant increase in inflammatory cells.\(^31\)

To the best of our knowledge, this is the first report of salivary biomarkers of bone turnover such as CTX, OC and ON in an Arab population. Abha is situated in the southern region of Asir, (Saudi Arabia) at an elevation of 2270 m above sea level. Since there are no earlier studies that mention levels of salivary biomarkers in periodontitis patients in Saudi Arabia or any other Arab nation, the results of this study can be used as reference range standard (Table 7) for salivary CTX, OC and ON for these people in periodontal disease, for screening of high-risk patients with family history of periodontitis and in clinical research.

Validation of this numerical scale is needed on a larger population.

We chose to use the Youden Index along with AUC to describe the biomarker’s ability for classifying disease status as YI provides maximum potential effectiveness of a biomarker. Unlike other studies, in biomarker development, levels of certain analyte may be unquantifiable below a limit of detection (LOD) and missing from the overall dataset. Disregarding these observations may negatively bias the ROC curve and thus Youden Index is also used. We have prepared a clinical interpretation based on cut-off levels because ROC areas under curve alone lack clinical interpretability. This is very significant as results of diagnostic tests would best benefit the clinician when expressed in terms of clinical gains and losses to the patients.

Within the limitations of this study, the results are novel and encouraging. Diabetic patients were included to increase the generalizability of the study as T2DM is very commonly seen in this population. One of the limitations of the study is that we included only T2DM patients who were on anti-hyperglycemic since we wanted to standardize the medications taken by the study population and during a pilot survey, a vast majority of patients attending our clinics were found to be using oral anti-hyperglycemic. To further increase its generalisability, this study should be

---

### Table 4
Post hoc analysis for comparative analysis of different salivary biomarkers between study groups.

| Variable     | Study Group | Group I | Group II | Group III |
|--------------|-------------|---------|----------|-----------|
| CTX          | Group I     |        | 0.000*   | 0.000*    |
|              | Group II    | 0.000*  |        | 0.001*    |
|              | Group III   | 0.000*  | 0.001*   |           |
| Osteocalcin  | Group I     |        | 0.000*   | 0.000*    |
|              | Group II    | 0.000*  |        | 0.000*    |
|              | Group III   | 0.000*  | 0.000*   |           |
| Osteonectin  | Group I     |        | 0.000*   | 0.000*    |
|              | Group II    | 0.000*  |        | 0.029*    |
|              | Group III   | 0.000*  | 0.029*   |           |

Note: *p value < 0.05; †p value < 0.01; ‡p value < 0.001; p value (Pearson Coefficient); BOP: Bleeding on probing; PPD: Probing pocket depth.

### Table 5
Correlational analysis – Periodontal variables with salivary biomarkers of bone turnover.

| Variable     | BOP (0.28) | PPD (0.79) | Bone Loss (0.82) | CTX (0.87) | Osteocalcin (0.85) | Osteonectin (0.85) |
|--------------|------------|------------|------------------|------------|-------------------|-------------------|
| CTX          | 0.007*     | 0.000*     | 0.000*           | —          | 0.000*            | 0.000*            |
| Osteocalcin  | 0.01*      | 0.000*     | 0.000*           | 0.000*     | —                 | 0.000*            |
| Osteonectin  | 0.005*     | 0.000*     | 0.000*           | 0.000*     | 0.000*            | —                 |

Note: *p value < 0.05; †p value < 0.01; ‡p value < 0.001; p value (Pearson Coefficient); BOP: Bleeding on probing; PPD: Probing pocket depth.
replicated in other population and regions in a longitudinal design and in patients with prediabetic and uncontrolled diabetes mellitus. Smokers which are another major risk factor for periodontal bone destruction should also be included in the next phase of the study to have a better understanding of the association of salivary biomarkers to periodontitis.

In conclusion, this study showed that salivary biomarkers of bone turnover (CTX, OC and ON) have a statistically significant difference between periodontally healthy and diseased groups. These correlated positively with PPD and BL with a statistically significant difference between

---

**Table 6** Cut off values, area under curve of ROC and Youden index of CTX, OC and ON in discriminating healthy from periodontitis based on BL, BOP and PPD.

| Source of the Curve | Se (%) | Sp (%) | AUC 95% CI | YI  |
|---------------------|--------|--------|-------------|-----|
| Bone loss CTX       | 19.87  | 96.7   | 89.7        | 0.958 0.92–1.00 | 0.85 |
| OC                  | 9.16   | 98.4   | 62.1        | 0.926 0.87–0.98 | 0.60 |
| ON                  | 66.70  | 95.1   | 86.2        | 0.934 0.87–0.99 | 0.81 |
| PPD                 | 19.87  | 100    | 77.8        | 0.914 0.84–0.99 | 0.77 |
| OC                  | 9.16   | 100    | 63.9        | 0.904 0.83–0.97 | 0.52 |
| ON                  | 66.70  | 100    | 75.0        | 0.915 0.84–0.98 | 0.77 |
| BOP                 | 19.87  | 72.0   | 62.5        | 0.704 0.53–0.87 | 0.34 |
| OC                  | 9.16   | 80.5   | 37.5        | 0.637 0.45–0.81 | 0.17 |
| ON                  | 66.70  | 69.5   | 62.5        | 0.684 0.50–0.86 | 0.31 |
| BOP                 | 29.86  | 69.5   | 62.5        | 0.53 0.34–0.78 | 0.31 |
| OC                  | 15.43  | 67.1   | 37.5        | 0.45 0.24–0.66 | 0.17 |
| ON                  | 72.85  | 69.5   | 62.5        | 0.31 0.10–0.52 | 0.17 |
| BOP                 | 31.80  | 68.3   | 62.5        | 0.31 0.10–0.52 | 0.17 |

Sensitivity (Se); Specificity (Sp); Receiver operator characteristic (ROC); Area under curve (AUC); 95% Confidence interval (CI); Youden Index (YI)Se + Sp-1; Probing pocket depth (PPD); Bleeding on probing (BOP).

---

**Figure 3** ROC curve of salivary biomarkers in terms of PPD.

**Figure 4** ROC curve of salivary biomarkers in terms of BOP.

---

**Table 7** Clinical interpretation and reference range of salivary biomarkers based on cut off values obtained from the coordinates of ROC curve and YI for identification of patients as healthy and periodontally diseased.

| Salivary Biomarker | Clinical patients | Cut off values |
|--------------------|-------------------|----------------|
| CTX ng/ml          | BL present        | 29.86 ng/ml and above |
|                    | PPD present       | 29.86 ng/ml and above |
|                    | BOP present       | — |
| OC ng/ml           | BL present        | 15.43 ng/ml and above |
|                    | PPD present       | 15.43 ng/ml and above |
|                    | BOP present       | — |
| ON ng/ml           | BL present        | 81.80 ng/ml and above |
|                    | PPD present       | 81.80 ng/ml and above |
|                    | BOP present       | — |

Receiver operator characteristics curve (ROC) curve; Youden Index (YI); Alveolar bone loss (BL); Probing pocket depth (PPD); Bleeding on probing (BOP).
healthy and diseased patients. It can be concluded that CTX, OC and ON have high discriminating power to identify most prominent clinical features of periodontitis. ie, BL and PPD. The reference range presented here may be used as a screening tool for identifying high risk patients at an early stage because timely detection of periodontal disease can be crucial in the clinical management of periodontal patients.

Conflicts of interest

The authors have stated explicitly that there are no conflicts of interest in connection with this article.

Acknowledgement

This study was supported by Research Grant from the Deanship of Scientific Research of King Khalid University, Abha, Saudi Arabia (Research grant no. 163/1439). The authors are thankful to the Deanship of Scientific research and Dean, College of Dentistry, King Khalid University for all the support in the conduct of this study. We also thank Dr Baiju KV Ph. D, Assistant Professor, Department of Statistics, Kerala, India for the advice and suggestions.

References

1. Highfield J. Diagnosis and classification of periodontal disease. Aust Dent J 2009;54:511–26.
2. Kuo TR, Chen CH. Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomarker Rev 2017;5:18.
3. Kanjevac T, Bijelic B, Brajkovic D, Vasovic M, Stolic R. Impact of chronic kidney disease mineral and bone disorder on jaw and alveolar bone metabolism: a narrative review. Oral Health Prev Dent 2018;16:79–85.
4. Scannapieco FA, Ng PBY, Hovey K, Hausmann E, Hutson A, Wactawski-Wende J. Salivary biomarkers associated with alveolar bone loss. Ann NY Acad Sci 2007;1098:496–7.
5. Gursoy UK, Könönen E, Pradhan-Palikhe P, et al. Salivary MMP-8, TIMP-1, and ICTP as markers of advanced periodontitis. J Clin Periodontol 2010;37:487–93.
6. Gursoy UK, Könönen E, Huunonen S, et al. Salivary type I collagen degradation end-products and related matrix metalloproteinases in periodontitis. J Clin Periodontol 2013;40:18–25.
7. Garnero P, Ferreras M, Karsdal MA, et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003;18:859–67.
8. Miricescu D, Totan A, Calenic B, et al. Salivary biomarkers: relationship between oxidative stress and alveolar bone loss in chronic periodontitis. Acta Odontol Scand 2014;72:42–7.
9. Baim S, Miller PD. Perspective: assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res 2009;24:561–74.
10. Xuan Y, Sun LH, Liu DM, et al. Positive association between serum levels of bone resorption marker CTX and HbA1c in women with normal glucose tolerance. J Clin Endocrinol Metab 2015;100:274–81.
11. Rosset EM, Trombeta-eSilva J, Hepfer G, Yao H, Bradshaw AD. SPARC and the N-propeptide of collagen I influence fibroblast proliferation and collagen assembly in the periodontal ligament. PLoS One 2017;12:e0173209.
12. Niknam S, Ghatreh-Samani K, Farrokhii E. The effect of adiponectin on osteogenenesis and vessel formation by oxidized low density lipoprotein-treated vascular smooth muscle cells. Cell Mol Med Open 2015;4:60–6.
13. Ng PY, Donley M, Hausmann E, Hutson AD, Rossmanno EF, Scannapieco FA. Candidate salivary biomarkers associated with alveolar bone loss: cross-sectional and in vitro studies. FEMS Immunol Med Microbiol 2007;49:252–60.
14. Naeem Z. Burden of diabetes mellitus in Saudi Arabia. Int J Health Sci 2015;9:5–6.
15. Alotaibi A, Perry L, Gholizadeh L, Al-Gammi A. Incidence and prevalence rates of diabetes mellitus in Saudi Arabia: an overview. J Epidemiol Glob Health 2017;7:211–8.
16. Caton J, Armitage G, Berglundh T, et al. A new classification scheme for periodontal and peri-implant diseases and conditions—Introduction and key changes from the 1999 classification. J Periodontal 2018;89:51–8.
17. Alnano J, Bay I. Problems and proposals for recording gingivitis and plaque. Int Dent J 1975;25:229–35.
18. Papapanou PN, Sanz M, Buduneli N, et al. Periodontitis: consensuses report of workshop 2 of the 2017 World workshop on the classification of periodontal and peri implant diseases and conditions. J Periodontal 2018;89:173–82.
19. Chapple IL, Mealey BL, Van Dyke TE, et al. Periodontal health and gingival diseases on an intact and a reduced periodontium: consensus report of workshop 1 of the 2017 World workshop on the classification of periodontal and peri implant diseases and conditions. J Clin Periodontol 2018;45:68–77.
20. Navazesh M, Kumar SK. Measuring salivary flow: challenges and opportunities. J Am Dent Assoc 2008;139:355–405.
21. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32–5.
22. Stånescu II., Totan A, Rus F, et al. Salivary diagnosis-clinical uses in assessing oral inflammation. Rev Chim 2017;68:1201–4.
23. Kinney JS, Morelli T, Braun T, et al. Saliva/pathogen biomarker signatures and periodontal disease progression. J Dent Res 2011;90:752–8.
24. Delany AM, Hankenson KD. Thrombospondin-2 and SPARC/osteonectin are critical regulators of bone remodelling. J Cell Commun Signal 2009;3:227–38.
25. Froedge BD, Ebersole JL, Kryscio RJ, Thomas MV, Miller CS. Bone remodelling biomarkers of periodontal disease in saliva. J Periodontol 2009;79:1913–9.
26. Nakashima K, Gholizadeh L, Al-Gammi A, et al. A longitudinal study of various crevicular fluid components as markers of periodontal disease activity. J Clin Periodontal 2011;40:1–5.
27. Dałezy AM, Hankenson KD. Thrombospondin-2 and SPARC/osteonectin are critical regulators of bone remodelling. J Cell Commun Signal 2009;3:227–38.
28. Froedge BD, Ebersole JL, Kryscio RJ, Thomas MV, Miller CS. Bone remodelling biomarkers of periodontal disease in saliva. J Periodontol 2009;79:1913–9.
29. Yoshihara A, Deguchi T, Hanada N. Relation of bone turnover markers to periodontal disease and jaw bone morphology in elderly Japanese subjects. Oral Dis 2009;15:176–81.
30. Roach HI. Why does bone matrix contain non-collagenous proteins? The possible roles of osteocalcin, osteonectin, osteopontin and bone sialoprotein in bone mineralisation and resorption. Cell Biol Int 1994;18:617–28.
31. Fernández-Real JM, Izquierdo M, Ortega F, et al. The relationship of serum osteocalcin concentration to insulin secretion, sensitivity, and disposal with hypocaloric diet and resistance training. J Clin Endocrinol Metab 2009;94:237–45.
32. Kos K, Wilding JP. SPARC: a key player in the pathologies associated with obesity and diabetes. Nat Rev Endocrinol 2010;6:225–35.
33. Yilmaz N, Uysal I, Eratilla V, et al. Effectos de la Diabetes Mellitus Inducida por Streptozotocina en el Hueso Alveolar de Ratas. Estudio Histopatológico e Inmunohistoquímico. Int J Morphol 2018;36:206–11.